Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Motor neuron disease (MND) is characterised by progressive neurological deterioration and coexistence of upper and lower motor neuron signs. Over the past decade, evidence has emerged of unique pathophysiological processes, including glutamate-mediated excitotoxicity, which has resulted in the development of novel diagnostic investigations and uncovered potential therapeutic targets. Advances in genetics, including the recently discovered C9orf72 gene, have radically changed the pathological mindset, from MND being classified as a neuromuscular disease to one that MND forms a continuum with other primary neurodegenerative disorders, including frontotemporal dementia. The present review will highlight the improvements that have occurred in clinical care, in conjunction with recent scientific developments.

Original publication

DOI

10.1111/imj.12874

Type

Journal article

Journal

Intern Med J

Publication Date

10/2015

Volume

45

Pages

1005 - 1013

Keywords

amyotrophic lateral sclerosis, biomarker, clinical trial, motor neuron disease, pathophysiology, treatment, Biomarkers, C9orf72 Protein, Clinical Trials as Topic, Disease Progression, Exercise, Humans, Motor Neuron Disease, Nutritional Support, Proteins